3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
4
Terminated
2
No longer available
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Breast Neoplasms
315
Lymphoma
282
Leukemia
227
Precursor Cell Lymphoblastic Leukemia-Lymphoma
216
Lymphoma, Non-Hodgkin
178
Leukemia, Lymphocytic, Chronic, B-Cell
177
Multiple Myeloma
174
Lymphoma, Large B-Cell, Diffuse
174
Lymphoma, Follicular
142
Leukemia, Myeloid, Acute
136
Lymphoma, Mantle-Cell
126
Hodgkin Disease
125
Burkitt Lymphoma
118
Myelodysplastic Syndromes
110
Lymphoma, Large-Cell, Immunoblastic
89
Lymphoma, B-Cell, Marginal Zone
85
Recurrence
67
Neoplasms, Plasma Cell
62
Leukemia, Myeloid, Chronic-Phase
59
Neuroblastoma
56
Dendritic Cell Sarcoma, Interdigitating
56
Leukemia, Myeloid, Accelerated Phase
55
Myeloproliferative Disorders
54
Melanoma
54
Congenital Abnormalities
48
Neoplasms
47
Leukemia, Myelomonocytic, Chronic
45
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
45
Blast Crisis
45
Lymphoma, Large-Cell, Anaplastic
44
Interventions
dacetuzumab
5
blinatumomab
4
Bortezomib
4
Lenalidomide
3
Dexamethasone
3
Rituximab
2
tetulomab tetraxetan lu-177
1
ponatinib
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
ibrutinib
1
ficlatuzumab
1
durvalumab
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Vorinostat
1
Methotrexate
1
Lutetium
1
KW-2478
1
Ifosfamide
1
Hsp90 inhibitor KU757
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Daunorubicin
1
Cyclophosphamide
1
Calcium Dobesilate
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Immunoproliferative Disorders
×
Cyclophosphamide
×
Clear all
NCT03349450
2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2
Completed
25 enrolled
18 charts